Key Takeaways
- Triptans are an effective first-line treatment for moderate to severe attacks, and acetaminophen or an oral NSAID is first-line for mild to moderate attacks. Take medication early in the attack.[1]
- Consider preventive therapy if you have four or more headaches a month, at least eight headache days a month, or attacks that stay disabling despite good acute treatment.[2]
- The American Headache Society's 2024 position statement says CGRP-targeting therapies should be considered a first-line option for migraine prevention, without first failing other preventive drug classes.[3]
- Using triptans on 10 or more days a month, or non-opioid pain relievers such as acetaminophen and NSAIDs on 15 or more days a month, for more than three months can cause medication overuse headache, a treatable but often missed diagnosis.[4][5]
- A sudden, severe (thunderclap) headache needs emergency evaluation, because the most common secondary cause is bleeding around the brain (subarachnoid hemorrhage).[6]
Migraine is a major cause of disability worldwide. In the Global Burden of Disease 2016 study, migraine accounted for 5.6% of all years lived with disability, behind only low back pain, and it is the leading cause of disability in people under 50.[7] Yet in clinical experience, most patients seen for the first time have either been undertreated for years, relying on over-the-counter medications that do not adequately control their attacks, or overtreated, taking acute medications so often that the medications themselves are now driving daily headaches.
The good news is that migraine management has changed substantially. Migraine-specific preventive therapies that target calcitonin gene-related peptide (CGRP) are now available, and the American Headache Society (AHS) found that their efficacy and tolerability are equal to or greater than those of the older first-line preventives. Its 2024 position statement update moved these therapies earlier: they should be considered a first-line option without a requirement for prior failure of other preventive drug classes.[3] Acute treatment options have also expanded with the gepants.
This guide covers what you need to know: how migraine is diagnosed, what the current treatment options look like, when preventive therapy makes sense, and how to avoid the common pitfalls that trap patients in a cycle of worsening headache.
What Migraine Actually Is
Migraine is not simply a "bad headache." It is a neurological disorder with defined diagnostic criteria. Untreated or unsuccessfully treated attacks last 4 to 72 hours. The pain has at least two of these features: one-sided location, pulsating quality, moderate or severe intensity, and worsening with (or avoidance of) routine physical activity. During the headache there is nausea or vomiting, or sensitivity to both light (photophobia) and sound (phonophobia).[8]
The underlying biology centers on calcitonin gene-related peptide (CGRP), the most abundant neuropeptide in the human trigeminal ganglia. CGRP plays a central role in the blood vessel widening and the peripheral and central sensitization of a migraine attack.[9] Triptans act on 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, which constricts cranial vessels and inhibits the release of pro-inflammatory neuropeptides.[10] Gepants and CGRP monoclonal antibodies target CGRP or its receptor directly.[9]
Migraine With Aura vs. Without Aura
Some people with migraine have aura: fully reversible visual, sensory, speech or language, motor, brainstem or retinal symptoms. At least one aura symptom spreads gradually over 5 minutes or more, and each aura symptom lasts 5 to 60 minutes. Visual aura is the most common type, occurring in over 90% of people with migraine with aura, at least in some attacks.[11]
Migraine with aura matters for contraception. The FDA label for one widely used combined estrogen-progestin pill (Yaz) groups women with a high risk of arterial or venous thrombotic disease as unable to use it, and that group includes women who have headaches with focal neurological symptoms, or migraine with or without aura if over age 35.[12] Tell whoever prescribes your contraception about your aura history. Certain aura types, such as hemiplegic migraine and migraine with brainstem aura, are also reasons to consider preventive therapy.[2]
Episodic vs. Chronic Migraine
Episodic migraine means fewer than 15 headache days per month.[9] Chronic migraine means headache on 15 or more days per month for more than three months, with migraine features on at least 8 of those days per month. The most common cause of symptoms that look like chronic migraine is medication overuse.[13] This progression is not inevitable: a recent review concluded that trial data support earlier use of CGRP therapies to help avoid chronification.[9]
Acute Treatment: Stopping an Attack
The goal of acute treatment is straightforward: stop the attack as quickly and completely as possible, and keep it from coming back within 24 hours. The critical principle is timing. Medication should be taken early in the attack.[1] In a Cochrane overview of sumatriptan, taking medication early, when pain was mild, was more effective than waiting until the pain was moderate or severe.[14]
Triptans: The First-Line Standard
Triptans are serotonin (5-HT1B/1D) receptor agonists[10] and are an effective first-line treatment for moderate to severe migraine.[1] Several triptans are available in the U.S.; they differ in dose forms, dosing limits and half-life.
Sumatriptan has the largest evidence base of the group: a Cochrane overview pooled data on 18 dose and route combinations in 52,236 participants. The subcutaneous 6 mg injection was the most effective route, reducing pain from moderate or severe to none at two hours in 59% of people versus about 15% with placebo; oral 50 mg gave complete relief in 28% versus 11% with placebo.[14] The injection works fastest but has more adverse events and a higher cost, so oral tablets are the practical choice for most patients.[14]
| Triptan | Forms | Labeled adult dose | Notes |
|---|---|---|---|
| Sumatriptan (Imitrex) | Tablets; subcutaneous injection | Tablets: 25, 50 or 100 mg; a second dose at least 2 hours later if needed; maximum 200 mg in 24 hours.[10] Injection: 6 mg; maximum 12 mg in 24 hours, as two 6 mg injections at least 1 hour apart.[15] | Most data. In the injection trials, relief began as early as 10 minutes after a 6 mg dose.[15] |
| Rizatriptan (Maxalt) | Tablets; orally disintegrating tablets (Maxalt-MLT) | 5 mg or 10 mg; a second dose 2 hours later if needed; maximum 30 mg in 24 hours.[16] | The orally disintegrating tablet dissolves on the tongue without liquid. The 10 mg dose may work better than 5 mg but may cause more side effects.[16] |
| Eletriptan (Relpax) | Tablets | 20 mg or 40 mg; maximum single dose 40 mg; a second dose at least 2 hours later if needed; maximum 80 mg per day.[17] | Do not take more than 40 mg at one time.[17] |
| Zolmitriptan (Zomig) | Tablets | Start with 1.25 mg or 2.5 mg; maximum single dose 5 mg; maximum 10 mg in 24 hours.[18] | Low starting doses with room to adjust.[18] |
| Frovatriptan (Frova) | Tablets | 2.5 mg; a second dose at least 2 hours later if needed; maximum 3 tablets (7.5 mg) in 24 hours.[19] | Long half-life of about 26 hours.[19] Rated effective for preventing menstrual migraine (Level A),[20] an off-label use. |
The sumatriptan (Imitrex) label lists these contraindications: ischemic coronary artery disease or coronary artery vasospasm; Wolff-Parkinson-White syndrome or related arrhythmias; a history of stroke or transient ischemic attack; hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; use of an ergotamine-containing medication or another 5-HT1 agonist (such as another triptan) within 24 hours; use of an MAO-A inhibitor now or within 2 weeks; and severe hepatic impairment.[10] Pregnancy is not on that list, but if you are pregnant or planning pregnancy, review your options with your physician. If you have cardiovascular risk factors, discuss them before starting a triptan.
NSAIDs and Acetaminophen
Strong evidence supports acetaminophen and oral NSAIDs as first-line treatments for mild to moderate migraine attacks. Typical doses studied include naproxen 500 mg (825 mg may be slightly more effective), ibuprofen 400 mg, and aspirin 1,000 mg. In a trial comparing sumatriptan plus naproxen (Treximet) with each medication alone, the combination was superior for partial pain relief at two hours.[1]
Acetaminophen is an option for patients who cannot take NSAIDs or triptans. The recommended dose is 1,000 mg, though acetaminophen was less effective than NSAIDs.[1]
Gepants: A New Class of Acute and Preventive Treatment
Gepants are small-molecule CGRP receptor antagonists.[21][22] Unlike the sumatriptan label, the ubrogepant and rimegepant labels do not list coronary artery disease, stroke or uncontrolled hypertension as contraindications, although both labels warn about hypertension and Raynaud's phenomenon.[10][21][22] This makes them an option to discuss when a triptan is not suitable.
- Ubrogepant (Ubrelvy): 50 mg or 100 mg tablet for acute migraine. A second dose may be taken at least 2 hours after the first if needed, up to 200 mg in 24 hours. It must not be combined with strong CYP3A4 inhibitors. Its approval trials measured pain freedom and freedom from the most bothersome symptom at 2 hours.[21]
- Rimegepant (Nurtec ODT): 75 mg orally disintegrating tablet, labeled both for acute treatment (75 mg as needed, maximum 75 mg in 24 hours) and for preventing episodic migraine (75 mg every other day).[22] The 2024 AHS position statement includes rimegepant and atogepant among the CGRP-targeting preventive therapies it supports as first-line.[3]
Anti-Nausea Medications
Nausea is a major barrier to effective acute treatment: if you cannot keep a tablet down, no oral medication will work. Antiemetics are often used for migraine. Metoclopramide and prochlorperazine are the most extensively studied, and both have been proven superior to placebo.[1] The 2025 AHS guideline update for emergency department care found IV prochlorperazine highly likely to be effective based on multiple high-quality (class I) studies and made it a Level A ("must offer") recommendation for eligible adults.[23]
Preventive Therapy: Who Needs It and What Works
Preventive therapy is underused. A family medicine review notes that many patients would benefit from prophylactic therapy, but only 3% to 13% obtain it.[2] That gap represents a large number of people experiencing preventable disability.
When to Consider Prevention
The American Academy of Family Physicians review recommends considering preventive therapy when any of the following apply:[2]
- Four or more headaches a month, or at least eight headache days a month
- Debilitating attacks despite appropriate acute treatment
- Difficulty tolerating, or a contraindication to, acute therapy
- Medication overuse headache
- Certain migraine subtypes, such as hemiplegic migraine or migraine with brainstem aura
- Patient preference
Successful prevention is defined as a 50% reduction in the number of headache attacks or days. Improvement may appear in six to eight weeks, but full effect can take up to six months.[2] Keep a headache diary during this period so you have objective data.
Traditional Oral Preventive Agents
| Medication | Typical Dose | Evidence Level | Key Considerations |
|---|---|---|---|
| Propranolol (Inderal LA) | Start 80 mg once daily; usual effective range 160 to 240 mg once daily. Stop if there is no satisfactory response within four to six weeks after reaching the maximal dose.[24] | Level A: effective[20] | Contraindicated in bronchial asthma, sinus bradycardia and heart block greater than first degree.[24] Side effects can include depression, fatigue, nightmares and erectile dysfunction.[2] |
| Topiramate (Topamax) | Titrated weekly from 25 mg to 100 mg/day, given in two divided doses.[25] | Level A: effective[20] | In pooled trial data, as effective as amitriptyline and propranolol.[2] Common side effects in migraine trials include paresthesia, weight loss, taste changes and difficulty with memory. Use in pregnancy can cause major birth defects, including cleft lip and/or palate.[25] |
| Amitriptyline | Start 10 mg; 25 to 150 mg once daily.[2] | Probably effective (rated lower because of a high rate of side effects)[2] | Sedation and anticholinergic effects are most common; weight gain and heart rhythm (QT) effects can occur. A good option for patients with depression or insomnia.[2] |
| Valproate/Divalproex (Depakote ER) | 500 mg once daily for 1 week, then 1,000 mg once daily.[26] | Level A: effective[20] | Boxed warnings for liver toxicity, fetal risk and pancreatitis. Contraindicated for migraine prevention in pregnancy and in women of childbearing potential who are not using effective contraception.[26] |
CGRP Monoclonal Antibodies: The New Standard
The first CGRP monoclonal antibody, erenumab, was approved in the U.S. in 2018.[27] All earlier first-line migraine preventives were developed for other conditions and adopted later for migraine; the CGRP-targeting therapies were developed specifically for migraine.[3]
Three self-injected antibodies are labeled for the preventive treatment of migraine in adults:
- Erenumab (Aimovig): 70 mg once monthly; some patients may benefit from 140 mg once monthly.[27] The open-label APPRAISE trial (2024) found that 56% of patients on erenumab cut their monthly migraine days by more than half, versus 16% on non-specific oral preventives.[9]
- Fremanezumab (Ajovy): 225 mg monthly, or 675 mg every 3 months given as three consecutive 225 mg injections.[28] In a 2026 network meta-analysis, fremanezumab ranked highest for both efficacy and safety.[29]
- Galcanezumab (Emgality): a 240 mg loading dose (two 120 mg injections), then 120 mg monthly. In its two episodic migraine trials, monthly migraine headache days fell by 4.7 and 4.3 days on 120 mg, versus 2.8 and 2.3 days on placebo.[30]
A fourth option, eptinezumab (Vyepti), is given as a 100 mg intravenous infusion every 3 months; some patients may benefit from 300 mg.[31]
The 2024 American Headache Society position statement update concluded that CGRP-targeting therapies should be considered a first-line approach for migraine prevention, along with the older first-line treatments, without a requirement for prior failure of other classes of preventive treatment.[3] This is an important shift, particularly for patients who have contraindications to older medications.
The side effect profile of CGRP antibodies is generally favorable. On the erenumab label, the most common side effects are injection site reactions and constipation, and the label warns about constipation with serious complications, hypertension and Raynaud's phenomenon.[27] Injection site reactions are the most common side effect on the fremanezumab and galcanezumab labels.[28][30] In a three-year open-label extension of erenumab, the safety profile was similar to earlier studies.[9] Insurance coverage can be a barrier: most plans use stepped care, requiring trials of other preventives before covering CGRP antibodies.[9]
Medication Overuse Headache: The Hidden Driver
Medication overuse is the most common cause of symptoms that look like chronic migraine.[13] Here is the paradox: the medications you are taking to relieve your headache are making you have more headaches.
The ICHD-3 diagnostic criteria for MOH require:[32]
- Headache occurring on 15 or more days per month in someone with a pre-existing headache disorder
- Regular overuse for more than three months of one or more drugs taken for acute or symptomatic treatment of headache
- The pattern is not better explained by another diagnosis
The usage threshold varies by medication class. Triptans,[4] opioids[33] and combination analgesics[34] count as overuse at 10 or more days per month for more than three months. Non-opioid pain relievers such as acetaminophen and NSAIDs count at 15 or more days per month.[5] ICHD-3 notes that these day counts are based on expert opinion rather than formal evidence.[32]
What I see most often in practice: a patient with episodic migraine starts using their acute medication more frequently as headaches intensify. The medication works, so they use it again. Over months, they shift from 4 headache days per month to 15 or more, with a dull background headache present most days. The acute medication still provides brief relief, reinforcing the behavior. By the time they see a physician, they often believe their migraine has simply "gotten worse," and they are partly right, but the medication is a significant driver.
Signs that you may be in medication overuse: daily or near-daily headache that is different from your typical migraine; acute medication works initially but the headache returns within hours; using acute medication on 10 or more days a month; feeling like you need to take something "just in case." If this sounds familiar, a physician evaluation is needed before simply stopping medications on your own, because withdrawal needs a supervised plan.
Treatment centers on a supervised plan to stop or cut back the overused medication. After withdrawal, migraine either reverts to an episodic pattern or remains chronic,[13] and medication overuse headache is itself a reason to consider preventive therapy.[2] A 2024 meta-analysis summarized in a 2025 review found that CGRP antibodies reduced medication overuse compared with placebo when the overused drugs were triptans or multiple drugs, though not simple analgesics.[9]
Menstrual Migraine
Menstrual migraine refers to attacks that cluster predictably around menstruation. The ICHD-3 research criteria for pure menstrual migraine use day 1 plus or minus 2 days, that is, from 2 days before to 3 days after the first day of bleeding.[35] Menstrually associated migraine is often prolonged and difficult to manage with conventional therapies.[36]
Two broad management strategies apply. The first is optimized acute treatment: using the most effective acute medication at the earliest sign of the attack. A long-acting triptan such as frovatriptan, with a half-life of about 26 hours, is one option.[19]
The second strategy is mini-prophylaxis: short-term preventive treatment around the expected period. In a randomized trial of 546 women, frovatriptan 2.5 mg once or twice daily for 6 days, starting 2 days before the expected menstrual migraine, lowered the share of women with a menstrual migraine from 67% on placebo to 52% (once daily) and 41% (twice daily).[36] The 2012 AAN/AHS guideline rated frovatriptan effective for preventing menstrual migraine (Level A).[20] This is an off-label use: the frovatriptan label states that it is not indicated for the prevention of migraine attacks.[19]
For women on hormonal contraception, the approach depends on aura and age. As noted above, a combined estrogen-progestin pill label lists headaches with focal neurological symptoms, and migraine with or without aura after age 35, among its contraindications.[12] Your physician can review non-estrogen options with you.
Triggers, the Headache Diary, and What Actually Causes Your Attacks
Every patient seen in clinical practice with migraine has a trigger they believe they need to eliminate. Chocolate, red wine, aged cheese. The reality is more complicated, and more useful.
Triggers do not cause migraine attacks directly. They lower the threshold in a brain that is already primed for an attack. Most attacks require multiple factors converging: hormonal changes plus poor sleep plus skipping a meal, for example. This means avoiding a single trigger often does not prevent attacks, and being overly restrictive about triggers can worsen quality of life without meaningful benefit.
Commonly reported, modifiable triggers include:
- Sleep disruption: both insufficient sleep and sleeping too much are triggers. Regular sleep timing matters for many migraine patients.
- Psychological stress: not only stress itself, but also the "let-down" after a stressful period (weekend migraine is a classic example).
- Hormonal changes: especially around menstruation.
- Skipped meals and dehydration: both can lower the migraine threshold in susceptible individuals.
- Caffeine: both excess intake and withdrawal can trigger attacks. Consistency matters; the goal is a stable, moderate intake, not elimination.
- Sensory stimuli: bright or flickering light, strong odors, and loud sustained noise can trigger attacks in some patients.
A headache diary, recording date, duration, severity, associated symptoms, possible triggers, and medications used, is the single most useful tool for identifying your personal pattern. It also provides the objective data your physician needs to assess preventive therapy response. Diary apps such as Migraine Buddy and N1 Headache are available, and many patients find them easier than paper.
Red Flags: When a Headache Is Not Migraine
Every physician who treats headache has at least one patient in mind who presented with "their usual migraine" and turned out to have a subarachnoid hemorrhage. The lesson is not to panic about every headache, but to apply systematic screening for warning signs.
The SNNOOP10 list summarizes red flags for secondary (dangerous) headache. Its core items include:[37]
- S: Systemic symptoms, including fever, and a history of cancer (neoplasm).
- N: Neurologic deficit, including decreased consciousness.
- O: Onset that is sudden or abrupt. A thunderclap headache needs urgent investigation because the most common secondary cause is subarachnoid hemorrhage.[6] This is the most critical red flag.
- O: Older age at onset: new headache starting after age 65.
- P: Pattern change, or recent onset of a new headache.
The list's other warning features include positional headache; headache brought on by sneezing, coughing or exercise; papilledema; progressive or atypical headache; pregnancy or the puerperium (the weeks after delivery); a painful eye with autonomic features; headache that starts after head trauma; immune system disorders such as HIV; and painkiller overuse or a new drug at headache onset.[37]
- The "worst headache of your life" or sudden, severe headache reaching max intensity in seconds
- Headache with fever, stiff neck, or rash
- Headache with new weakness, numbness, vision loss, or speech changes
- Headache after head trauma
- Headache in pregnancy or in the weeks after delivery
- Headache lasting more than 72 hours (status migrainosus)
Status Migrainosus
Status migrainosus is a debilitating migraine attack lasting more than 72 hours. Breaks of up to 12 hours due to medication or sleep still count toward that duration.[38] By the time patients seek help, they have often already used their usual acute medications without adequate relief.
Management escalates beyond typical outpatient options. For adults treated in the emergency department for a migraine attack, the 2025 AHS guideline update says IV prochlorperazine and greater occipital nerve block must be offered (Level A); IV ketorolac, IV metoclopramide and subcutaneous sumatriptan should be offered (Level B); and IV dexamethasone and IV valproate may be offered (Level C). It made no recommendation for normal saline (Level U).[23] IV dexamethasone can also be considered to help decrease headache recurrence.[1]
Do not try to manage status migrainosus at home. If your migraine has lasted more than two days and is not improving, seek care.
Managing Migraine Through Telehealth
Much of migraine care is well suited to telehealth. The diagnosis of migraine is clinical, made from the history rather than from imaging or lab tests, and the ongoing management of a known diagnosis requires physician review, not physical examination, in most cases.
What we do effectively via telehealth at TeleDirectMD:
- Initial evaluation of headache history to diagnose episodic or chronic migraine
- Prescribing and refilling acute medications (triptans, gepants, anti-nausea agents)
- Initiating and monitoring preventive therapy, including CGRP monoclonal antibodies when appropriate
- Reviewing headache diary data to assess treatment response and adjust plans
- Identifying medication overuse headache and developing a supervised withdrawal plan
- Discussing hormonal considerations for women with migraine, including contraception guidance
In-person or specialist evaluation remains important for new or changing headache patterns that warrant imaging, for suspected hemiplegic or basilar migraine, for patients who have failed multiple preventive therapies, and when neurological examination is required. We will refer appropriately when that bar is met.
To reach us: call 678-956-1855 or email contact@teledirectmd.com.
References
- Mayans L, Walling A. Acute Migraine Headache: Treatment Strategies. Am Fam Physician. 2018;97(4):243-251. https://www.aafp.org/pubs/afp/issues/2018/0215/p243.html
- Ha H, Gonzalez A. Migraine Headache Prophylaxis. Am Fam Physician. 2019;99(1):17-24. https://www.aafp.org/pubs/afp/issues/2019/0101/p17.html
- Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;64(4):333-341. https://pubmed.ncbi.nlm.nih.gov/38466028/
- Headache Classification Committee of the International Headache Society. ICHD-3: 8.2.2 Triptan-overuse headache. Accessed November 7, 2026. https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/8-2-2-triptan-overuse-headache/
- Headache Classification Committee of the International Headache Society. ICHD-3: 8.2.3 Non-opioid analgesic-overuse headache. Accessed November 7, 2026. https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/8-2-3-simple-analgesic-overuse-headache/
- Chen CY, Fuh JL. Evaluating thunderclap headache. Curr Opin Neurol. 2021;34(3):356-362. https://pubmed.ncbi.nlm.nih.gov/33661161/
- Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. Editorial. https://pubmed.ncbi.nlm.nih.gov/29468450/
- Headache Classification Committee of the International Headache Society. ICHD-3: 1.1 Migraine without aura. Accessed November 7, 2026. https://ichd-3.org/1-migraine/1-1-migraine-without-aura/
- Nicol KS, Burkett JG. Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine. Curr Pain Headache Rep. 2025;29(1):55. https://pmc.ncbi.nlm.nih.gov/articles/PMC11861264/
- GlaxoSmithKline. IMITREX (sumatriptan) tablets, prescribing information. Revised 12/2025. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=584abe73-8290-4484-ff8e-5890831c095e
- Headache Classification Committee of the International Headache Society. ICHD-3: 1.2 Migraine with aura. Accessed November 7, 2026. https://ichd-3.org/1-migraine/1-2-migraine-with-aura/
- Bayer HealthCare Pharmaceuticals. YAZ (drospirenone and ethinyl estradiol) tablets, prescribing information. Revised 5/2023. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065f33e4-b587-4e66-b896-ca9ab7b7c876
- Headache Classification Committee of the International Headache Society. ICHD-3: 1.3 Chronic migraine. Accessed November 7, 2026. https://ichd-3.org/1-migraine/1-3-chronic-migraine/
- Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults: overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;2014(5):CD009108. https://pmc.ncbi.nlm.nih.gov/articles/PMC6469574/
- GlaxoSmithKline. IMITREX (sumatriptan) injection, prescribing information. Revised 12/2025. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee7d073-0b99-48f2-7985-0d8cf970894b
- Organon. MAXALT and MAXALT-MLT (rizatriptan benzoate), prescribing information. Revised 6/2021. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007b4644-e0e7-4863-9ae3-fe09676b3f5f
- Viatris. RELPAX (eletriptan hydrobromide) tablets, prescribing information. Revised 1/2024. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e
- Amneal Pharmaceuticals. ZOMIG (zolmitriptan) tablets, prescribing information. Revised 3/2022. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=101d7dd3-3970-4025-b6ca-79d28020f99d
- Amneal Pharmaceuticals. Frovatriptan succinate tablets, prescribing information. Revised 9/2019. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94b996dc-ddc4-41ce-9a9f-3d91cb187473
- Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-1345. https://pubmed.ncbi.nlm.nih.gov/22529202/
- Allergan. UBRELVY (ubrogepant) tablets, prescribing information. Revised 6/2025. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab
- Pfizer. NURTEC ODT (rimegepant) orally disintegrating tablets, prescribing information. Revised 4/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d
- Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2025;66(1):53-76. https://pubmed.ncbi.nlm.nih.gov/41321235/
- ANI Pharmaceuticals. INDERAL LA (propranolol hydrochloride) extended-release capsules, prescribing information. DailyMed, updated August 24, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734
- Janssen Pharmaceuticals. TOPAMAX (topiramate), prescribing information. Revised 3/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21628112-0c47-11df-95b3-498d55d89593
- AbbVie. DEPAKOTE ER (divalproex sodium) extended-release tablets, prescribing information. Revised 3/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dc024ce-efc8-4690-7cb5-639c728fccac
- Amgen. AIMOVIG (erenumab-aooe) injection, prescribing information. Revised 3/2025. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b998ed05-94b0-47fd-b28f-cddd1e128fd8
- Teva. AJOVY (fremanezumab-vfrm) injection, prescribing information. Revised 6/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e344ea-5916-4947-b6f2-4a76ccc04b6b
- Shakir I, Shahzad F, Shabbir A, et al. Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network meta-analysis. Eur J Clin Pharmacol. 2026;82(2):27. https://pubmed.ncbi.nlm.nih.gov/41546694/
- Eli Lilly. EMGALITY (galcanezumab-gnlm) injection, prescribing information. Revised 6/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a147be-233a-40e8-a55e-e40936e28db0
- Lundbeck. VYEPTI (eptinezumab-jjmr) injection for intravenous use, prescribing information. Revised 6/2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79065861-6aa5-4d1f-829f-3a6471286b36
- Headache Classification Committee of the International Headache Society. ICHD-3: 8.2 Medication-overuse headache (MOH). Accessed November 7, 2026. https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/
- Headache Classification Committee of the International Headache Society. ICHD-3: 8.2.4 Opioid-overuse headache. Accessed November 7, 2026. https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/8-2-4-opioid-overuse-headache/
- Headache Classification Committee of the International Headache Society. ICHD-3: 8.2.5 Combination-analgesic-overuse headache. Accessed November 7, 2026. https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/8-2-5-combination-analgesic-overuse-headache/
- Headache Classification Committee of the International Headache Society. ICHD-3 Appendix: A1.1.1 Pure menstrual migraine without aura. Accessed November 7, 2026. https://ichd-3.org/appendix/a1-migraine/a1-1-migraine-without-aura/a1-1-1-pure-menstrual-migraine-without-aura/
- Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63(2):261-269. https://pubmed.ncbi.nlm.nih.gov/15277618/
- Do TP, Remmers A, Schytz HW, Schankin C, Nelson SE, Obermann M, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2018;92(3):134-144. https://pmc.ncbi.nlm.nih.gov/articles/PMC6340385/
- Headache Classification Committee of the International Headache Society. ICHD-3: 1.4.1 Status migrainosus. Accessed November 7, 2026. https://ichd-3.org/1-migraine/1-4-complications-of-migraine/1-4-1-status-migrainosus/